But it will be up to doctors whether to use the combo in Darzalex-exposed patients.
ApexOnco Front Page
Recent articles
Persevera is a bust, but Roche hasn’t given up on the front line.
The company hands its PD-L1 x VEGF bispecific back to ImmuneOnco.
Seven oncology approvals included nods for subcutaneous Rybrevant and Lunsumio.
Mocertatug rezetecan is starting its first western pivotal trials.
PersonGen’s LV009 takes the industry tally of clinical-stage projects to 14.
The holiday period included Genmab’s discontinuation of acasunlimab.
Nenocorilant features among the latest industry projects newly into phase 1.
